|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
49,820,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$ - $ |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile ALX Oncology Holdings is a holding company. Through its subsidiaries, Co. is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on capabilities in protein engineering and oncology led by the CD47 blocker, evorpacept. Co.'s primary product candidate, evorpacept, is a CD47 blocking biologic in development as a combination therapy with other anti-cancer agents for treatment of various oncology indications, including myelodysplastic syndromes, acute myeloid leukemia, head and neck squamous cell carcinoma, gastric/gastroesophageal junction and breast cancer.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
12,000 |
16,400 |
16,400 |
16,400 |
Total Buy Value |
$102,338 |
$152,109 |
$152,109 |
$152,109 |
Total People Bought |
1 |
2 |
2 |
2 |
Total Buy Transactions |
1 |
2 |
2 |
2 |
Total Shares Sold |
117,404 |
137,404 |
153,952 |
173,687 |
Total Sell Value |
$1,478,153 |
$1,701,189 |
$1,946,164 |
$2,108,214 |
Total People Sold |
3 |
3 |
4 |
4 |
Total Sell Transactions |
7 |
8 |
13 |
22 |
End Date |
2024-04-07 |
2024-01-05 |
2023-07-07 |
2022-07-07 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Pons Jaume |
President & CEO |
|
2023-07-25 |
4 |
A |
$0.00 |
$0 |
D/D |
89,000 |
625,538 |
|
- |
|
Randolph Sophia |
Chief Medical Officer |
|
2023-07-25 |
4 |
A |
$0.00 |
$0 |
D/D |
34,000 |
315,477 |
|
- |
|
Garcia Peter S |
Chief Financial Officer |
|
2023-07-25 |
4 |
A |
$0.00 |
$0 |
D/D |
32,000 |
86,738 |
|
- |
|
Pinto Shelly |
VP, Finance and CAO |
|
2023-07-06 |
4 |
S |
$6.52 |
$47,889 |
D/D |
(7,345) |
55,713 |
|
- |
|
Pinto Shelly |
VP, Finance and CAO |
|
2023-06-30 |
4 |
S |
$7.34 |
$3,420 |
D/D |
(466) |
63,058 |
|
- |
|
Pons Jaume |
President & CEO |
|
2023-06-30 |
4 |
S |
$7.34 |
$23,547 |
D/D |
(3,208) |
536,538 |
|
- |
|
Randolph Sophia |
Chief Medical Officer |
|
2023-06-30 |
4 |
S |
$7.34 |
$11,781 |
D/D |
(1,605) |
281,477 |
|
- |
|
Garcia Peter S |
Chief Financial Officer |
|
2023-06-30 |
4 |
S |
$7.34 |
$6,511 |
D/D |
(887) |
54,738 |
|
- |
|
Randolph Sophia |
Chief Medical Officer |
|
2023-06-09 |
4 |
OE |
$1.91 |
$48,171 |
D/D |
12,829 |
283,082 |
|
- |
|
Pons Jaume |
President & CEO |
|
2022-12-29 |
4 |
S |
$11.07 |
$35,779 |
D/D |
(3,232) |
539,746 |
|
- |
|
Randolph Sophia |
Chief Medical Officer |
|
2022-12-29 |
4 |
S |
$11.07 |
$17,901 |
D/D |
(1,617) |
270,253 |
|
- |
|
Garcia Peter S |
Chief Financial Officer |
|
2022-12-29 |
4 |
S |
$11.07 |
$9,886 |
D/D |
(893) |
53,723 |
|
- |
|
Pinto Shelly |
VP, Finance and CAO |
|
2022-12-29 |
4 |
S |
$11.07 |
$5,336 |
D/D |
(482) |
62,097 |
|
- |
|
Randolph Sophia |
Chief Medical Officer |
|
2022-12-16 |
4 |
OE |
$1.91 |
$189,875 |
D/D |
46,474 |
271,870 |
|
- |
|
Pinto Shelly |
VP, Finance and CAO |
|
2022-08-05 |
4 |
A |
$0.00 |
$0 |
D/D |
11,000 |
62,718 |
|
- |
|
Pons Jaume |
President & CEO |
|
2022-08-05 |
4 |
A |
$0.00 |
$0 |
D/D |
74,000 |
542,978 |
|
- |
|
Randolph Sophia |
Chief Medical Officer |
|
2022-08-05 |
4 |
A |
$0.00 |
$0 |
D/D |
37,000 |
225,396 |
|
- |
|
Garcia Peter S |
Chief Financial Officer |
|
2022-08-05 |
4 |
A |
$0.00 |
$0 |
D/D |
29,000 |
55,178 |
|
- |
|
Garcia Peter S |
Chief Financial Officer |
|
2022-02-07 |
4 |
OE |
$4.08 |
$67,305 |
D/D |
15,000 |
24,483 |
|
- |
|
Pons Jaume |
President & CEO |
|
2022-02-03 |
4 |
OE |
$0.99 |
$35,186 |
D/D |
24,154 |
468,978 |
|
- |
|
Pinto Shelly |
VP, Finance and CAO |
|
2022-01-28 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
50,446 |
|
- |
|
Randolph Sophia |
Chief Medical Officer |
|
2021-12-15 |
4 |
OE |
$0.99 |
$33,788 |
D/D |
23,852 |
188,396 |
|
- |
|
Lettmann Jason |
Director |
|
2021-12-13 |
4 |
S |
$25.29 |
$8,901,804 |
I/I |
(325,377) |
285,956 |
|
- |
|
Plain Henry A Jr |
10% Owner |
|
2021-12-13 |
4 |
S |
$25.29 |
$1,287,431 |
I/I |
(48,390) |
285,956 |
|
- |
|
Plain Henry A Jr |
10% Owner |
|
2021-12-10 |
4 |
S |
$30.77 |
$822,719 |
I/I |
(26,274) |
291,758 |
|
- |
|
111 Records found
|
|
Page 2 of 5 |
|
|